Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

News provided by

May 04, 2017, 13:19 ET

LONDON, May 4, 2017 /PRNewswire/ -- Summary

Download the full report: https://www.reportbuyer.com/product/4883823/

Rheumatoid arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years (Lefèvre et al., 2009). Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. RA can have a substantial impact on quality of life and place a considerable economic burden upon the patient.

The advent of biologic disease-modifying anti-rheumatic drugs (DMARD) has boosted the rheumatoid arthritis (RA) market tremendously over the last two decades. The South-East Asia market, which for the purposes of this report comprises South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, is forecast to grow at a compound annual growth rate (CAGR) of 4.7%, from USD1.04 Billion in 2015 to USD1.44 Billion in 2022. South Korea accounted for most of the market in 2015 with a 29.9% share, followed by Malaysia with 19.0%, the Philippines with 14.2%, Vietnam with 9.4%, Taiwan with 8.5%, Indonesia with 7.1%, Singapore with 6.4%, and Thailand with 5.5%.

The entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly and Incyte's baricitinib, Regeneron's sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson's sirukumab, Astellas' peficitinib (ASP015K), and AbbVie's upadacitinib. Galapagos' filgotinib is in late-stage development, but it will not be launched during the forecast period, as its Phase III trial completion date is in Q3 2020.

The therapeutic market for RA has become extremely competitive owing to the number of new drug approvals. Competition for tumor necrosis factor alpha (TNF-?) inhibitors is particularly fierce and now dominates the treatment market for RA patients who are refractory to first-line DMARDs. In 2015, Humira (adalimumab), MabThera/Rituxan (rituximab) and Remicade (infliximab) were ranked among the top-10 best-selling drugs in the world, with global revenue of USD14.01 Billion, USD7.33 Billion and USD6.56 Billion, respectively, reflecting their groundbreaking clinical and commercial success.

The report "Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs" provides an introduction to rheumatoid arthritis (RA), covering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and co-morbidities and complications. Disease classification and methods of diagnosis are also provided.

In addition, this report also provides the following analysis -
- Provides an overview of the RA marketed products landscape, including product profiles of key marketed products and heat maps that compare the safety and efficacy parameters of the various drugs.
- Analyzes the RA pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target. The chapter concludes with an analysis of promising pipeline molecules, including product profiles and a heatmap that compares the efficacy and safety data for the various drugs.
- Provides detailed analysis of recent clinical trials in RA by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
- Supplies forecasts for the RA market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015–2022 period. The eight South-East Asia markets are covered and data are presented at a country level.
- Provides detailed analysis of key market drivers and barriers for RA in South-East Asia markets.

Companies mentioned in this report: Eli Lilly and Incyte's baricitinib, Regeneron's sarilumab, GlaxoSmithKline (GSK) and Johnson & Johnson's sirukumab, Astellas' peficitinib (ASP015K), and AbbVie's upadacitinib. Galapagos' filgotinib

Scope

The current South-East Asia RA market contains novel products, including Xeljanz, a JAK inhibitor; and Actemra (tocilizumab), an IL-6 receptor inhibitor.
- What are the competitive advantages of the existing novel drugs?
There are over 450 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
- What is the potential for pipeline products to address unmet needs in the RA market?
Analysis of clinical trials since 2006 identified that the failure rates of RA molecules were highest in Phase II, at 72.6%, with the overall attrition rate for RA standing at 94.6%.
- How do failure rates vary by stage of development, molecule type, and molecular target?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia RA therapeutics market is expected to increase in value at a CAGR of 4.7%, from $1.04 billion to over $1.4 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising RA prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
- Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?

Reasons to buy

This report will enable you to -
- Understand the clinical context of RA by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
- Consider market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in RA by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
Download the full report: https://www.reportbuyer.com/product/4883823/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com